GVHD characteristics
| Characteristic . | Acute onset (n = 352) . | Chronic onset (n = 388) . |
|---|---|---|
| Median time from transplantation to diagnosis, mo (range) | 3.6 (2.4-20.9) | 4.4 (2.2-28.2) |
| Type of onset, no. (%) | ||
| De novo (late*) | 43 (12) | 66 (17) |
| Quiescent (recurrent*) | 265 (75) | 264 (68) |
| Progressive (persistent*) | 44 (13) | 58 (15) |
| Sites involved at onset, no. (%) | ||
| Skin | 190 (54) | 261 (67) |
| Eyes | 0 | 92 (24) |
| Mouth | 0 | 333 (86) |
| Liver | 106 (30) | 136 (35) |
| Gastrointestinal tract | 218 (62) | 118 (30) |
| Other | 0 (0) | 39 (10) |
| No. of sites involved at onset (%) | ||
| 1 or 2 | 328 (93) | 207 (53) |
| 3 | 24 (7) | 134 (35) |
| More than 3 | 0 | 47 (12) |
| Dose of prednisone at onset (%) | ||
| None | 165 (47) | 204 (53) |
| More than 0 but less than 0.5 mg/kg | 92 (26) | 85 (22) |
| 0.5-1.0 mg/kg | 56 (16) | 60 (15) |
| More than 1.0 mg/kg | 39 (11) | 39 (10) |
| Platelet count less than 100 000/μL at onset, no. (%) | 173 (49) | 165 (43) |
| Serum bilirubin level more than 2 mg/dL at onset, no. (%) | 60 (17) | 58 (15) |
| Characteristic . | Acute onset (n = 352) . | Chronic onset (n = 388) . |
|---|---|---|
| Median time from transplantation to diagnosis, mo (range) | 3.6 (2.4-20.9) | 4.4 (2.2-28.2) |
| Type of onset, no. (%) | ||
| De novo (late*) | 43 (12) | 66 (17) |
| Quiescent (recurrent*) | 265 (75) | 264 (68) |
| Progressive (persistent*) | 44 (13) | 58 (15) |
| Sites involved at onset, no. (%) | ||
| Skin | 190 (54) | 261 (67) |
| Eyes | 0 | 92 (24) |
| Mouth | 0 | 333 (86) |
| Liver | 106 (30) | 136 (35) |
| Gastrointestinal tract | 218 (62) | 118 (30) |
| Other | 0 (0) | 39 (10) |
| No. of sites involved at onset (%) | ||
| 1 or 2 | 328 (93) | 207 (53) |
| 3 | 24 (7) | 134 (35) |
| More than 3 | 0 | 47 (12) |
| Dose of prednisone at onset (%) | ||
| None | 165 (47) | 204 (53) |
| More than 0 but less than 0.5 mg/kg | 92 (26) | 85 (22) |
| 0.5-1.0 mg/kg | 56 (16) | 60 (15) |
| More than 1.0 mg/kg | 39 (11) | 39 (10) |
| Platelet count less than 100 000/μL at onset, no. (%) | 173 (49) | 165 (43) |
| Serum bilirubin level more than 2 mg/dL at onset, no. (%) | 60 (17) | 58 (15) |
New categorization of GVHD according to 2005 NIH consensus criteria.4